Prognostic value of residual cancer burden after neoadjuvant taxane-anthracycline chemotherapy in phenotypic subsets of breast cancer

被引:0
|
作者
Hubbard, R.
Peintinger, F.
Liedtke, C.
Hatzis, C.
Kuerer, H. M.
Valero, V.
Buzdar, A. U.
Hortobagyi, G. N.
Pusztai, L.
Symmans, W. F.
机构
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Gen Hosp Loeben, Leoben, Austria
[3] Nuvera Biosci Inc, Woburn, MA USA
关键词
D O I
10.1200/jco.2008.26.15_suppl.544
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
544
引用
收藏
页数:1
相关论文
共 50 条
  • [41] High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy
    Zhang, Huikun
    Zhao, Yawen
    Liu, Xiaoli
    Fu, Li
    Gu, Feng
    Ma, Yongjie
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] The prognostic significance of Ki-67 expression before and after neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes
    Zhang, J.
    Zhang, X.
    Yu, F.
    Liu, J.
    Zhang, S.
    Hao, X.
    Hou, G.
    CANCER RESEARCH, 2013, 73
  • [43] Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients
    Lim, Emerson A.
    Gunther, Jacqueline E.
    Kim, Hyun K.
    Flexman, Molly
    Hibshoosh, Hanina
    Crew, Katherine
    Taback, Bret
    Campbell, Jessica
    Kalinsky, Kevin
    Hielscher, Andreas
    Hershman, Dawn L.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 162 (03) : 533 - 540
  • [44] Diffuse optical tomography changes correlate with residual cancer burden after neoadjuvant chemotherapy in breast cancer patients
    Emerson A. Lim
    Jacqueline E. Gunther
    Hyun K. Kim
    Molly Flexman
    Hanina Hibshoosh
    Katherine Crew
    Bret Taback
    Jessica Campbell
    Kevin Kalinsky
    Andreas Hielscher
    Dawn L. Hershman
    Breast Cancer Research and Treatment, 2017, 162 : 533 - 540
  • [45] ASO Visual Abstract: Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy
    Erin A. Elder
    Chad A. Livasy
    Erin E. Donahue
    Brittany Neelands
    Alicia Patrick
    Mckenzie Needham
    Terry Sarantou
    Lejla Hadzikadic-Gusic
    Arielle L. Heeke
    Richard L. White
    Annals of Surgical Oncology, 2022, 29 : 8071 - 8071
  • [46] Prognostic value of Bcl-2 in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy
    Vargas-Roig, L. M.
    Cuello-Carrion, F. D.
    Fernandez-Escobar, N.
    Daguerre, P.
    Leuzzi, M.
    Ibarra, J.
    Gago, F. E.
    Nadin, S. B.
    Ciocca, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy
    Agarwal, Reshu
    Philip, Arun
    Pavithran, Keechilat
    Rajanbabu, Anupama
    Goel, Gaurav
    Vijaykumar, D. K.
    INDIAN JOURNAL OF CANCER, 2019, 56 (03) : 228 - 235
  • [48] The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review
    Timmermans, M.
    van der Hel, O.
    Sonke, G. S.
    Van de Vijver, K. K.
    van der Aa, M. A.
    Kruitwagen, R. F.
    GYNECOLOGIC ONCOLOGY, 2019, 153 (02) : 445 - 451
  • [49] Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore
    Steenbruggen, Tessa G.
    van Seijen, Maartje
    Janssen, LiseloreM.
    van Ramshorst, Mette S.
    van Werkhoven, Erik
    Peeters, Marie-Jeanne T. D. F. Vrancken
    Wesseling, Jelle
    Lips, Esther H.
    Sonke, Gabe S.
    CLINICAL CANCER RESEARCH, 2019, 25 (16) : 4985 - 4992
  • [50] Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer
    Peintinger, F.
    Kuerer, H. M.
    McGuire, S. E.
    Bassett, R.
    Pusztai, L.
    Symmans, W. F.
    BRITISH JOURNAL OF SURGERY, 2008, 95 (04) : 433 - 437